ArticleScientific reports2025
DFT investigation of iron-doped boron nitride nanoparticles for anastrozole drug delivery and molecular interaction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Highly efficient lanthanum- and actinium-doped B6/B8 complexes as single-atom catalysts toward superior hydrogen evolution reaction: a DFT perspective.Journal of molecular modeling · 2025Article
- MD-enhanced DFT investigation of β-cyclodextrin as drug delivery system for Ampyra drug.RSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The development of efficient drug delivery systems is critical for improving therapeutic outcomes and reducing side effects in cancer treatment. This study investigates the potential of iron-doped boron nitride nanoparticles (Fe-BNNPs) as a nanocarrier for Anastrozole, a key aromatase inhibitor used in breast cancer therapy. Using density functional theory (DFT), we systematically analyzed the interaction mechanisms between Anastrozole and Fe-BNNPs, focusing on binding energies, electronic properties, and structural stability. Our results reveal a strong adsorption of Anastrozole on Fe-BNNPs, with binding energies ranging from - 0.6 to - 1.4 eV, indicating a stable and efficient drug-carrier interaction. Iron doping significantly enhances the reactivity of BNNPs, improving drug loading and release capabilities. Nanoparticles passivated with -H and -OH groups and functionalized with iron nanoclusters were examined, demonstrating that -H passivation yields more stable structures compared to -OH, despite minor variations in electronic properties such as energy gaps (e.g., 2.51 eV for -H vs. 2.54 eV for -OH). The incorporation of iron nanoclusters further increases the binding energy of Anastrozole by approximately 40%, highlighting its role in optimizing drug-nanocarrier interactions. Optical absorption spectra reveal distinct peaks for Anastrozole adsorption on -H and -OH passivated surfaces, providing a clear indicator of interaction states. These findings underscore the potential of Fe-BNNPs as a promising nanocarrier for targeted Anastrozole delivery, offering enhanced precision and therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.